|
[1]
|
Stewart, E.A., Laughlin-Tommaso, S.K., Catherino, W.H., Lalitkumar, S., Gupta, D. and Vollenhoven, B. (2016) Uterine Fibroids. Nature Reviews Disease Primers, 2, Article 16043. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Sohn, G.S., Cho, S., Kim, Y.M., Cho, C., Kim, M. and Lee, S.R. (2018) Current Medical Treatment of Uterine Fibroids. Obstetrics & Gynecology Science, 61, 192-201. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Cermik, D., Arici, A. and Taylor, H.S. (2002) Coordinated Regulation of HOX Gene Expression in Myometrium and Uterine Leiomyoma. Fertility and Sterility, 78, 979-984. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Okoro, C.C., Ikpeze, O.C., Eleje, G.U., Udigwe, G.O., Ezeama, C.O., Ugboaja, J.O., et al. (2024) Association between Serum Vitamin D Status and Uterine Leiomyomas: A Case-Control Study. Obstetrics & Gynecology Science, 67, 101-111. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
De La Cruz, M.S. and Buchanan, E.M. (2017) Uterine Fibroids: Diagnosis and Treatment. American Family Physician, 95, 100-107.
|
|
[6]
|
Lee, M.J., Yun, B.S., Seong, S.J., Kim, M., Jung, Y.W., Kim, M.K., et al. (2017) Uterine Fibroid Shrinkage after Short-Term Use of Selective Progesterone Receptor Modulator or Gonadotropin-Releasing Hormone Agonist. Obstetrics & Gynecology Science, 60, 69-73. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Navarro, A., Bariani, M.V., Yang, Q. and Al-Hendy, A. (2021) Understanding the Impact of Uterine Fibroids on Human Endometrium Function. Frontiers in Cell and Developmental Biology, 9, Article 633180. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Daniilidis, A., Angioni, S. and D’Alterio, M.N. (2021) Highlights on Medical Treatment of Uterine Fibroids. Current Pharmaceutical Design, 27, 3821-3832. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Lee, S. and Stewart, E.A. (2023) New Treatment Options for Nonsurgical Management of Uterine Fibroids. Current Opinion in Obstetrics & Gynecology, 35, 288-293. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Duhan, N. (2011) Current and Emerging Treatments for Uterine Myoma—An Update. International Journal of Women’s Health, 3, 231-241. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Choe, Y.S., Lee, W.M., Choi, J.S., Bae, J., Eom, J.M. and Choi, E. (2019) Clinical Characteristics of Patients with Leiomyoma Who Undergo Surgery after High Intensity Focused Ultrasound (HIFU). Obstetrics & Gynecology Science, 62, 258-263. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Yerezhepbayeva, M., Terzic, M., Aimagambetova, G. and Crape, B. (2022) Comparison of Two Invasive Non-Surgical Treatment Options for Uterine Myomas: Uterine Artery Embolization and Magnetic Resonance Guided High Intensity Focused Ultrasound—Systematic Review. BMC Women’s Health, 22, Article No. 55. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Yang, X., Chen, Z., Qiu, T., Liu, Y., Ren, H., Luo, W., et al. (2025) Lichong Decoction Improves Inflammatory Microenvironment and Alleviates Fibrosis in Uterine Leiomyoma via Targeting CXCL8. Journal of Ethnopharmacology, 340, Article 119276. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
王熙月, 伍涛. 中医药治疗子宫肌瘤的研究进展[J]. 中国当代医药, 2023, 30(9): 34-39.
|
|
[15]
|
Hu, D., Wang, H., Yu, L., Guan, Z., Jiang, Y., Hu, J., et al. (2024) The Role of Ginkgo Folium on Antitumor: Bioactive Constituents and the Potential Mechanism. Journal of Ethnopharmacology, 321, Article 117202. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
汤友苗, 孔成才, 范文秀, 等. 白果内酯对子宫肌瘤细胞及裸鼠移植瘤的影响实验研究[J]. 陕西医学杂志, 2025, 54(2): 152-157.
|
|
[17]
|
Sahin, K., Orhan, C., Tuzcu, M., Sahin, N., Ozercan, I.H., Kabil, N., et al. (2024) The Role of Curcumin in Preventing Naturally Occurring Leiomyoma in the Galline Model. Pharmaceuticals, 17, Article 1732. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
伍茂玉, 卢圣友. 逍遥散加减联合温针灸疗法治疗寒凝气滞血瘀证子宫肌瘤的临床观察[J]. 中国药物滥用防治杂志, 2024, 30(12): 2336-2337.
|
|
[19]
|
钱诚, 叶利群, 陈嫣. 《近现代25位中医名家妇科经验》出版血府逐瘀汤治疗子宫肌瘤患者的临床疗效及血清激素水平观察[J]. 介入放射学杂志, 2024, 33(8): 942.
|
|
[20]
|
李冬华, 张武芳, 刘新敏, 等. 扶正祛瘀中药“理冲汤”治疗子宫肌瘤的疗效观察[J]. 辽宁中医杂志, 2018, 45(8): 1653-1656.
|
|
[21]
|
张丽杰, 赵雪莲, 李亚男. 理冲汤加减联合子宫穴温针灸对子宫肌瘤患者子宫血流和性激素水平的影响[J]. 四川中医, 2024, 42(1): 161-164.
|
|
[22]
|
丁书云, 耿寻寻, 江飞云. 平胃散联合米非司酮治疗痰瘀互结型子宫肌瘤疗效观察及对性激素、子宫血流动力指标水平的影响[J]. 湖北中医药大学学报, 2025, 27(1): 104-107.
|
|
[23]
|
张祥, 温晓梨, 程碧婷, 等. 桂枝茯苓丸治疗子宫肌瘤的临床应用与药理作用研究进展[J/OL]. 中国实验方剂学杂志, 2024: 1-13. 2025-06-23.[CrossRef]
|
|
[24]
|
陈旖雯, 赖芊, 邓泽欣, 等. 何若苹运用六味地黄丸治疗子宫肌瘤术后的经验探讨[J]. 浙江中医药大学学报, 2024, 48(10): 1240-1243.
|
|
[25]
|
丁玉, 李梦雅, 冯珂, 等. 化瘀消瘤方对子宫肌瘤患者疗效分析[J/OL]. 辽宁中医杂志, 2024: 1-9.
http://kns.cnki.net/kcms/detail/21.1128.R.20241216.1004.108.html, 2025-06-23.
|
|
[26]
|
马雨彤, 路振凯, 谢雁鸣. 消结安胶囊治疗子宫肌瘤气滞血瘀证药品临床综合评价[J]. 中国实验方剂学杂志, 2025, 31(8): 235-243.
|
|
[27]
|
朱倩梦, 周玉珍, 陈惠娴, 等. 蒋氏扶正消癥方辅助治疗子宫肌瘤的疗效观察[J]. 辽宁中医杂志, 2025, 52(2): 94-98.
|
|
[28]
|
吴中恺, 张婷婷, 史杨, 等. 活血化瘀中药对子宫肌瘤Wnt信号转导通路的抑制因子SFRP1表达的影响[J/OL]. 辽宁中医杂志, 2025: 1-11.
http://kns.cnki.net/kcms/detail/21.1128.r.20250313.1220.049.html, 2025-06-23.
|
|
[29]
|
王丽, 李苑瑛, 高萍, 等. 消瘤汤对子宫肌瘤患者血清肿瘤标志物、雌激素及血管内皮生长因子水平的影响[J]. 中华中医药学刊, 2023, 41(9): 160-162.
|
|
[30]
|
齐振荣, 韩超. 自拟活血消癥汤联合米非司酮对子宫肌瘤术后气虚血瘀证患者激素水平及卵巢功能的影响[J]. 国际中医中药杂志, 2019, 41(6): 569-572.
|
|
[31]
|
陈秀英, 陈娜, 高娜, 等. 消结化瘤汤对子宫肌瘤患者血清性激素和IL-22、TNF-α水平的影响[J]. 四川中医, 2024, 42(3): 167-170.
|
|
[32]
|
程海英. 贺普仁学术思想与经验传承[J]. 北京中医药, 2012, 31(4): 243-245.
|
|
[33]
|
邓越, 王桂玲, 李嘉慧, 等. 贺氏温通法联合常规针刺法治疗子宫肌瘤气滞血瘀型临床观察[J]. 实用中医药杂志, 2024, 40(3): 586-589.
|
|
[34]
|
孙芳园, 卢明, 沈伟鸿. 肠三针治疗脓毒症肠功能障碍的临床疗效观察[J]. 蚌埠医学院学报, 2021, 46(10): 1357-1359.
|
|
[35]
|
孙月华, 李宛平. 黄芪建中汤联合针灸对虚寒型胃痉挛患者胃肠激素及TNF-α、hs-CRP 水平的影响[J]. 光明中医, 2021, 36(6): 889-891.
|
|
[36]
|
孙莉, 孙建, 李敏敏, 等. 胃肠三针调神针法联合桂枝茯苓丸对开腹子宫肌瘤剔除术后胃肠功能恢复、应激反应及炎症水平的影响[J]. 中华中医药学刊, 2024, 42(8): 212-215.
|